Clinical trial
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV…
NCT00028366 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00028366 |
|---|---|
| Title | Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People |
| Official title | A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected Subjects With Virologic Treatment Failure |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate |
| Enrollment | 56 |
| Completion | Jul 1, 2005 |
| First posted | Dec 28, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: